DUBLIN--(BUSINESS WIRE)--The "Hyperphosphatemia - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Scope
- The report provides a snapshot of the pipeline development for Hyperphosphatemia
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Hyperphosphatemia
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Hyperphosphatemia
- The report also covers the dormant and discontinued pipeline projects related to Hyperphosphatemia
- 3SBio Inc.
-
Ardelyx Inc.
- Daiichi Sankyo Company Ltd.
- Medice Arzneimittel Putter GmbH & Co. KG
- OPKO Health Inc.
- PDX Pharmaceuticals LLC
- Shield Therapeutics PLC
Key Topics Covered
1. Report Introduction
2. Hyperphosphatemia Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Hyperphosphatemia
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8h762c/2018_pipeline?w=4